 3  0 
The Acquired Immunodeficiency Syndrome (AIDS) is caused by the 4 8
Human Immunodeficiency Virus (HIV), which was identified in 1983 (1,2) from New latent virus reactivating compounds, also called latency reversing 8 0 agents (LRA), when used conjointly with ART, are capable to eliminate 1 0 0 latent HIV is positively correlated with NF-κB activation, demonstrating the 1 0 1 importance of this factor in latency reactivation (19, 20). Several of these compounds are derived from secondary metabolics of plants, popularly known in Brazil as Janauba or leiterinha and is used, in traditional 1 1 0 medicine, as a latex preparation (diluted in water) for the treatment of gastric 1 1 1 disorders, such as peptic ulcer and gastritis, as well as neoplastic diseases, compounds previously tested in the reactivation assays. Cell viability 1 7 5 assessment was performed in 10 4 cells plated in 96-well plates, in three 1 7 6 independent experiments, each in sextuplicates. After 5 days of culture, vital 1 7 7 resazurin dye (CellTiter Blue, Promega) was added to the cells and absorbance 1 7 8 levels were evaluated by spectrophotometer at 595 nm. Analysis of the activation of PKCs. To assess the mechanism of action of 1 8 0 HIV latency reactivation by Janauba compounds, 10 5 J-Lat cells in 24-well 1 8 1 plates were treated with different specific inhibitors of PKCα, PKCδ and PKCγ 1 8 2 isoforms Go6976, Go6983, Ro-31-8220, respectively, for 24 hours (36-38). The following concentrations of the alcoholic extract were tested: 0.01 µg/mL 1 8 7 and 0.001 µg/mL and the percentage of GFP positive cells was assessed by In addition, PKC activation was evaluated by immunofluorescence to detect 1 9 0 cytosolic location of different PKC isoforms. For this, 10 4 HeLa cells were plated 1 9 1 in black 96-well glass bottom plates. These cells were transfected with three 1 9 2 different plasmids encoding three PKC isoforms fused to GFP (PKCα-GFP, PKCδ-GFP and PKCγ-GFP) for 24 hours and then treated with 1 μ g/mL and 0.1 anti-CD8 mAbs were added to the PBMC (2 x 10 5 /tube) and incubated for 30 2 9 4 min at room temperature in the dark. The cells were washed with PBS and then for 20 min. After washing, the antibodies for intracellular staining (anti-IL-17-2 9 7
PECy7, anti-IFN-γ-PE-Cy5, anti-IL-10-PE-Cy7, anti-IL-21-PE) or the 2 9 8 corresponding anti-IgG1 isotype control, were added in various combinations RT-PCR with Abbott M2000 Sq HIV VL technology. JALEx isolation from Euphorbia umbellate and chemical analysis.
The JALEx soluble in water and ethanol was characterized mainly by a indicated that triterpenes was predominant throughout the whole extract, with 
Reactivation of latent HIV by JALEx and its cytotoxicity effects
In this work, we used the alcoholic extracts from JALEx resuspended in The cells were exposed to increasing concentrations of JALEx, ranging from 10 3 3 8
to 10 -7 µg/mL. The reactivation of latent HIV was evaluated by GFP reporter cytotoxicity, JALEx at 10 μ g/mL was also toxic for J-Lat 10.6, whereas the other reactivate virus from latency models. In order to evaluate whether JALEx activation of HIV transcription is with different PKC inhibitors (Gö6666, Gö6983 and Rö31-8220) to prevent 3 5 8
JALEx stimulation. After this period, the cells were incubated with non cytotoxic 3 5 9
concentrations of JALEx (0.01 and 0.001 µg/mL). PMA is a phorbol ester that
activates different isoforms of PKCs and was used as positive control (1 µM). Rö31-8220 before JALEx treatment either at concentration 0.01 or 0.001 µg/mL. This result suggests that JALEx is a pan activator of different isoforms of PKCs with non treated cells. is essential for its auto-phosphorylation and, consequently, its cellular activation experiments, two concentrations of JALEx (0.01 µg/mL and 0.001 µg/mL) were were collected at different time points (10 and 30 minutes; 1, 6 and 24 hours).
9 5
We observed that the phosphorylation of conventional PKCs, identified by anti- 24 hours after the treatments (Fig. S2A, upper panels) . The same pattern was least up to 6 hours of stimulation (Fig. S2B ). However, as suggested by the WB JALEx is a pan activator of PKC isoforms. PKC isoforms (α, δ and γ ) (Fig. 4A) . The same results were obtained with 4 2 5 longer treatment scheme (up to 24h) (Fig. 4B ). Finally, these results showed 4 2 6
that JALEx promotes activation of different classes of PKC through 4 2 7
phosphorylation followed by downstream relocation to the plasma membrane. However, we confirmed the NF-kB translocation to the nucleus after 24 hours of 4 4 3
JALEx treatment, once NF-kB staining was located in the nuclei (Fig. 5B ). To We also evaluated the recruitment of NF-κB to the HIV promoter by WT) or harboring mutations that prevent NF-κB interaction (17, 50, 51).
5 5
Transfected cells were treated with 1 μ g/mL of JALEx and luciferase activity 4 5 6
was assessed 24 hours later. Our results showed that JALEx treatment induced 4 5 7
a 5-fold increase in luciferase expression in cells transfected with pNF-kB WT.
5 8
However, no luciferase activity was observed in cells transfected with pNF-kB 4 5 9
MUT (Fig. 5D) CCR5 expression levels (Fig. 6A ). The same pattern was observed for cells 4 7 3 treated with PMA ( Fig. 6A) . Indeed, JALEx treatment also induced the compared to non-treated cells, and with PMA control (Fig. 6B) . Figure 6C shows virus receptors and co-receptors. 1/MCAF, IFNγ and TNF-α (Fig. 6D) . Overall, the highest concentration of JALEx 4 8 7
(10 µg/mL) induced the same levels of cytokines as did PMA positive control. pg/mL, respectively (Fig. 6D) . Those results showed that JALEx activate T 4 9 0
CD4 + cells in order to secrete important pro-inflammatory cytokines involved in Progression for AIDS in HIV-1 positive patients is mainly characterized 4 9 7
by CD4 + T cell depletion specifically Th1 and Th17 cells, which impact 4 9 8 negatively on immune protection against different opportunistic pathogens. We under ART treatment. We found that JALEx at 1 μg/mL increases HIV viral load 5 0 1 up to 1.5 log compared with non treated PBMC cells (Fig. 7A ). This data was with no correspondence in T CD8 + cells (Fig. 7B) . In order to investigate the 5 0 5
immune response in those patients we evaluate cytokine production in T CD4 induction was higher compared to PMA positive controls (Fig. 7C) . Moreover, CD4 + and CD8 + T cells, but also Th1 and Th17-like subsets positives for IL-21 5 1 1 (Fig. 7D) . In contrast, no difference was observed regarding either IFN-γ or IL- secreting protective levels of IL-21.
1 7
JALEx reactivation effects in latently SIV-infected macaque cells 5 1 8
Finally, we explored the capacity of JALEx to reactivate latent viruses in 5 1 9
CD4 + lymphocytes from SIVmac239-infected cynomolgus macaques. We 5 2 0
purified resting memory CD4 + T cells from a single viremic macaque and 5 2 1 prepared serial dilution replicates of these cells to seed into quantitative viral 5 2 2 outgrowth assays (QVOA). Cells in these assays were stimulated in triplicate at HIV/SIV through PKC pathway (ingenol and concanavalin A). In order to 5 2 5
compare the ability of these compounds to reactivate latent SIV, we measured other cultures (Table S1 ). However, JALEx was the only compound capable of In this work we addressed the ability of an ethanolic extract obtained and these activities requires both PKCα and PKCθ isoforms activation (52).
4 6
Modifications in phorbol ring can lead molecules able to induce carcinogenesis CD4+lymphocytes in ex vivo experiments (17).
6 5
In our study we used JALEx to explore its capability to reactivate HIV three different PKC inhibitors (G6666, G6983 and Ro-31-8220). In our assays 5 7 2
Gö6983 was more powerful inhibitor totally blocking HIV reactivation in both J-5 7 3
Lat cell lines. Go 6983 is a fast pan-PKC inhibitor against PKCα, PKCβ, PKCγ 5 7 4
and PKCδ with IC 50 in low nM range then JALEx could be reactivating latent 5 7 5
HIV through the activation of different PKC isoforms. Additionally, we showed 5 7 6
that JALEx activates the PKC pathway by promoting NF-κB internalization into 5 7 7
the nucleus and increasing HIV transcription, which is dependent on NF-κB 5 7 8
binding to LTR promoter. Using image and western blot analysis we showed 5 7 9
that JALEx was able to activate classical and novel PKC isoforms such as: the the IL-2 gene. PKCθ also promotes T cell cycle progression (57).
8 8
We also evaluate the capacity of JALEx to induce cytokines production in 5 8 9
human PBMC cells in vitro. This pattern of alteration in the production of 5 9 0 cytokines from treatment with reactivating compounds is quite common in the 5 9 1 case of the shock and kills strategy, which aims to activate the cells and 
